Hanmi Mulls New Trial Strategy As ZAI Lab Ends Olmutinib Partnership
Hanmi is reviewing a new global clinical trial plan for its novel lung cancer drug olmutinib after China's ZAI Lab returned its rights, and following Boehringer’s cancellation of a major-licensing deal in 2016. ZAI's decision may reflect the difficulties faced by olmutinib and other third generation EGFR inhibitors in competing with Tagrisso, as well as the increasingly crowded and rapidly changing non-small cell lung cancer space.
You may also be interested in...
Several South Korean companies are set to present updates on their growing lung cancer pipelines at a major meeting in Chicago this month, underlining the high unmet needs and strong R&D interest in this area by firms in the country.
Celgene reworks its collaboration with Abide, dropping its buyout option. Roivant gains Chinese rights to anti-infective lemafulin and adds a fifth candidate to Dermavant's pipeline, while pSivida acquires Icon and FDA-approved Dexycu for cataract surgery inflammation.
Johnson & Johnson's Zytiga and Pfizer's Sutent generated the most cumulative sales from 2006-2017, while Bristol's Opidvo and Pfizer's Ibrance were the most successful launches, according to an analysis of cancer drug launches by Leerink.